Physician profile
Benjamin C Schaffer
NPI 1245283902
$2,987.57
in general payments reported to CMS, 2019-2025
26 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $615 · 2021: $211 · 2022: $231 · 2023: $421 · 2024: $476 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.90 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $806.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $375.69 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $287.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $179.46 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $154.29 | 2023-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $134.20 | 2020-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $128.25 | 2023-2024 | Qulipta |
| Biohaven Pharmaceutical Holding Company Ltd. | $118.13 | 2022 | |
| Viiv Healthcare Company | $116.41 | 2019-2025 | Dovato |
| Pfizer INC. | $101.36 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $67.40 | 2024-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $65.43 | 2022-2024 | Quviviq |
| Gilead Sciences, INC. | $61.07 | 2019-2025 | |
| Kerecis Limited | $60.61 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.49 | 2020-2024 | Xifaxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.16 | 2024 | Otezla, Repatha |
| Smith+Nephew, INC. | $35.21 | 2019 | |
| Melinta Therapeutics, LLC | $35.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.81 | 2020 | |
| Acell, INC. | $26.94 | 2019-2020 | |
| Allergan, INC. | $26.40 | 2019 | |
| Lundbeck LLC | $18.29 | 2024 | Rexulti |
| Organogenesis INC. | $16.82 | 2019 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Convatec INC. | $15.95 | 2019 | |
| Esperion Therapeutics, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Schaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.